in a company like glaxosmithkline is that you have a lot of moving parts.eration of old , aicines go off patent significant headwind, but it has to happen. those things have to be replaced. focused on iseen building a platform for growth to take us forward for the next 10-15 years. we did the transaction with novartis to build the world leading consumer health care company and vaccine company. i believe we have an innovation portfolio that's going to drive our pharmaceuticals business over the next decade. that is what we are focused on executing. we think it can deliver real value. importantly, it allows us to grow organically, not to commit enormous amounts of capital to buy another business. so, i understand that people focus on the share price, but they shouldn't forget the money that we paid back over the last seven years to shareholders. like pfizer say they are at a competitive disadvantage. if pfizer and allegan go ahead and foreign -- fisa becomes a formal neutral company -- >> we are a u.k. domicile company. we pay our taxes where we make our prof

. >> first, though, up next, glaxosmithkline ceo speaks with us in a first on cnbc interview. find out which drugs in their pipeline he thinks have the biggest blockbuster potential when we come back. when you're not confident your company's data is secure, the possibility of a breach can quickly become the only thing you think about. that's where at&t can help. at at&t we monitor our network traffic so we can see things others can't. mitigating risks across your business. leaving you free to focus on what matters most. i'm a senior field technician for pg&e here in san jose. pg&e is using new technology to improve our system, replacing pipelines throughout the city of san jose, to provide safe and reliable services. raising a family here in the city of san jose has been a wonderful experience. my oldest son now works for pg&e. when i do get a chance, an opportunity to work with him, it's always a pleasure. i love my job and i care about the work i do. i know how hard our crews work for our customers. i want them to know that they do have a safe and reliable system. together,

. >> walter kelly represents beth in her lawsuit against the drug manufacturer, glaxosmithkline. >> our primary goal is to make sure one, these children have the resources necessary to get the best possible medical care for the rest of their life. >> the company told fox 25 we believe the allegations in these lawsuits are entirely unfounded and that the drug has proper labeling, was marketed appropriately, and did not cause the injuries alleged. in fact t there are conflicting studies if the drug causes heart defect, cleftly or cleft pallet. nearly 60 lawsuits have been filed nationwide and the cases have been consolidated to a massachusetts courtroom. tonight at 10:00 p.m., we take a look at how one doctor is already making changes on how she prescribes the drug. for fox 25 investigates, i'm sara underwood. >> mark: quincy place with a warning tonight about a phishing scam circulating on line. victims receive tan email like this that appears to be from xfinity, it asks for personal information in order to process a payment. a request for social security and credit card numbers. police

glaxosmithkline was also part of the study.etting underway at this hour in kansas city as the royal celebrate their second world series championship in franchise history. expected 200,000 people the pack into the parade route and the downtown kansas city. -- into downtown kansas city. you can find the latest news on bloomberg.com. scarlet: you know how mark is not here to talk about the parade? nursing his mets hangover. director is not looking at his screen. they are a better team, sorry, mets. let's go back to julie hyman where the computer is working again. that about the mets because he doesn't care about sports. julie: i could say the same thing. let's look at stocks. my graphics are working again. we are seeing all three major averages training higher today. his energy that pushing the averages higher. group is up by 2.6%. helped in part by earnings reports, and it's also the lift in oil prices that's helping matters today. there are a couple of different things that are boosting the price of oil today, a bit of a setback

glaxosmithkline bought a similar drug.thereuy is more cash in the company than the price i paid. i'm looking forward to the future of this medicine. alix: it seems like the chatter after the filing came out is that this could be a reverse merger. >> i don't see a reason or need to reverse merge turing. very few people have focused on is drug and no one's asked me why i did this. why do you think it's worth so much more than what you pay for it? it's not a stock market game or trick. this is about dying patients in a drug that can work for those patients.0 turing is doing great and can ipo anytime it wants. we are focused on creating value. kalabios, i expect we can announce an acquisition for them to acquire new product by the end of this year. . we are in talks with three separate acquisitions that can create more value. scarlet: would this be drugs for common or rare diseases? >> probably rare diseases. 2 of them are not fda approved and one is. they are progressing rapidly in could be great fits. scarlet: when it comes

scarlet: erik schatzker had a chance to sit down with the ceo of glaxosmithkline yesterday. could be done about drug pricing. >> we have to get some sensible discussion about the facts, more transparency. sensible people from all sides of the conversation start to get together and think about how we involve this. what we all want is -- i want us to see great medicines being made to the people available -- being made available to the people who need them. we need to make sure the incentive for innovation remains. susan devore is the ceo of premier, the company that helps hospitals make buying decisions. you wound up helping hospitals get equipment and get drugs. you helped negotiate that price. what are you seeing in the drug pricing world? susan: we wake up every day trying to figure out how we will help make health care safer, higher-quality and lower-cost. 98% of our ceos would say drug pricing and drug shortages are one of the biggest challenges that they face. we tried to bring friction, competitive friction to these markets to drive the price of the product down and lin